ReviewCurrent gastroenterology reports2018
Strategies for Effective Discontinuation of Proton Pump Inhibitors.
Review in Current gastroenterology reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Proton pump inhibitors and the risk of gastric cancer: a systematic review, evidence synthesis and life course epidemiology perspective.BMJ open gastroenterology · 2025Pooled it
- Refractory Diarrhea After Dor Fundoplication: The Long-Term Impact of Proton Pump Inhibitor Therapy.Cureus · 2025Article
- The effect of proton-pump inhibitor therapy on disease outcomes in inflammatory bowel disease: a population-based cohort study.Therapeutic advances in gastroenterology · 2025Article
- Maintenance Proton Pump Inhibitor Use Associated with Increased All-Cause and Cause-Specific Mortality in Sweden.Digestive diseases and sciences · 2023Article
- Deprescribing Strategies: A Prospective Study on Proton Pump Inhibitors.Journal of clinical medicine · 2023Article
- Population-based cohort study: proton pump inhibitor use during pregnancy in Sweden and the risk of maternal and neonatal adverse events.BMC medicine · 2022Article
- Effect of proton pump inhibitors in infants with esophageal atresia on the gut microbiome: a pilot cohort.Gut pathogens · 2022Article
- A Randomized Open-Label Study of Two Methods of Proton Pump Inhibitors Discontinuation.Cureus · 2021Article
- Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden.Journal of gastroenterology · 2020Article
- Alginates: From the ocean to gastroesophageal reflux disease treatment.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019Article
- A cross-sectional study of national outpatient gastric acid suppressant prescribing in the United States between 2009 and 2015.PloS one · 2018Article
- Cardiovascular Risk of Proton Pump Inhibitors.Methodist DeBakey cardiovascular journalReview
- [Therapeutic Approach to Gastroesophageal Reflux Disease].Acta gastroenterologica LatinoamericanaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewProton pump inhibitors (PPIs) are effective for many conditions but are often overprescribed. Recent concerns about long-term risks have made patients re-evaluate their need to take PPIs chronically, though these population-based studies have methodological weaknesses. The goal of this review is to provide evidenced-based strategies for discontinuation of PPI therapy. RECENT
findingsGiven that some patients experience rebound symptoms when abruptly stopping continuous PPI therapy due to its effect on hypergastrinemia, strategies focus on avoiding rebound. Tapering the PPI and then initiating a "step-down" approach with the use of alternative medications may be effective. "On-demand therapy" provides patients with the option to take intermittent PPI courses, reducing overall use and cost while preserving patient satisfaction. It is important for providers to consider ambulatory pH or pH/impedance testing to rule out diagnoses that may require alternative medications like neuromodulators. A number of studies reviewed here can provide guidance in counseling patients on PPI discontinuation. It is important for the provider to obtain a baseline needs assessment for PPI therapy and to elucidate predictors of difficulty in discontinuation prior to initiating a strategy.
Indexed as
Identifiers
29767318What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.